Drug intelligence / Profile preview

iPSC-CL

Development stage: Phase 1
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intramyocardial

Overview

iPSC-CL is an autologous cell therapy product consisting of cardiac lineage cells derived from induced pluripotent stem cells (iPSCs). The therapy involves reprogramming a patient's own somatic cells into iPSCs, then differentiating them into cardiac lineage cells, which are subsequently transplanted back into the patient. This approach is being investigated for treating congenital heart disease and heart failure, with the potential benefit of avoiding immune rejection since the cells originate from the patient's own tissue.

Other names: autologous induced pluripotent stem cells of cardiac lineage

Beyond the preview

Go deeper on iPSC-CL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPSC-CL.

Explore the full profile